The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Alzheimer's disease: strategies for disease modification
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
The neurobiology of zinc in health and disease
Frederickson, C. J., Koh, J.-Y., & Bush, A. I. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1671 · Cited by 1,850
Uber eine eigenartige Erkrankung der Hirnrinde
Alzheimer, A. (1907) · Medical Entomology and Zoology · Cited by 1,503
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“The first of these compounds, clioquinol, has been reported to drastically reduce amyloid pathology in APP transgenic mic”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“However, Notch cleavage was not found to be blocke”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Protease Inhibitors: Current Status and Future Prospects
Leung, D., Abbenante, G., & Fairlie, D. P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990412m · Cited by 883
Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?
Gerlai, R. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)20020-7 · Cited by 881
Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain
Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., De Saint Andrieu, P., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E., Holsztynska, E. J., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00012.x · Cited by 875
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 860
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 818
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · cited 1×
“In particular, Phase II data of the amino-terminal antibody bapineuzumab (already in Phase III trials), presented at ICAD 2008, and published late last yea”
BackgroundThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703
Bace1 modulates myelination in the central and peripheral nervous system
Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608
Milano, J., McKay, J., Dagenais, C., Foster-Brown, L., Pognan, F., Gadient, R., Jacobs, R. T., Zacco, A., Greenberg, B., & Ciaccio, P. J. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh254 · Cited by 576
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546
2009 Alzheimer's disease facts and figures
Alzheimer's Association (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.03.001 · Cited by 543
Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Non-Steroidal Anti-Inflammatory Drugs: Current Status and Rational Therapeutic Use
Hart, F. D., & Huskisson, E. C. (1984) · Drugs · doi:10.2165/00003495-198427030-00004 · Cited by 507
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide
Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A. M., Berezovska, O., Hyman, B. T., Chang, T. Y., Tanzi, R. E., & Kovacs, D. M. (2001) · Nature Cell Biology · doi:10.1038/ncb1001-905 · Cited by 392
McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H. L., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F., et al. (2006) · Nature Medicine · doi:10.1038/nm1423 · Cited by 368
Fleisher, A. S., Raman, R., Siemers, E. R., Becerra, L., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 307
Current Status and Future Prospects
Wood, C., Baker, G., & Trounson, A. (1984) · Clinical In Vitro Fertilization · doi:10.1007/978-1-4471-3317-9_2 · Cited by 300
Association of metabolic syndrome with Alzheimer disease: A population-based study
Vanhanen, M., Koivisto, K., Moilanen, L., Helkala, E. L., Hänninen, T., Soininen, H., Kervinen, K., Kesäniemi, Y. A., Laakso, M., & Kuusisto, J. (2006) · Neurology · doi:10.1212/01.wnl.0000234037.91185.99 · Cited by 295
Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290
Development of tau aggregation inhibitors for alzheimer's disease
Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286
Substrate-targeting γ-secretase modulators
Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 280
Cholesterol and the Biology of Alzheimer's Disease
Wolozin, B. (2004) · Neuron · doi:10.1016/s0896-6273(03)00840-7 · Cited by 275
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255
Velliquette, R. A., O'Connor, T., & Vassar, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2350-05.2005 · Cited by 254
Active and passive immunotherapy for neurodegenerative disorders
Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250
Liang, X., Wang, Q., Hand, T., Wu, L., Breyer, R. M., Montine, T. J., & Andreasson, K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3591-05.2005 · Cited by 226
Handbook of Clinical Neurology
Mastaglia, F. L., & Hilton‐Jones, D. (2007) · UWA Profiles and Research Repository (UWA) · Cited by 220
Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer
BACHURIN, S., BUKATINA, E., LERMONTOVA, N., TKACHENKO, S., AFANASIEV, A., GRIGORIEV, V., GRIGORIEVA, I., IVANOV, Y., SABLIN, S., & ZEFIROV, N. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03654.x · Cited by 219
Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits
Hrncic, R., Wall, J., Wolfenbarger, D. A., Murphy, C. L., Schell, M., Weiss, D. T., & Solomon, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64639-1 · Cited by 213
Eckman, C. B., & Eckman, E. A. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051101 · Cited by 200
β-Secretase inhibition for the treatment of Alzheimer's disease – promise and challenge
Citron, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.12.004 · Cited by 194
Self-citationTau protein, the paired helical filament and Alzheimer's disease
Goedert, M., Klug, A., & Crowther, R. A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s323 · Cited by 194
Craft, S. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213866.86934.7e · Cited by 167
Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration
Frenkel, D., Katz, O., & Solomon, B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11455 · Cited by 167
Martone, R., Zhou, H., Atchison, K., Comery, T., Xu, J. Z., Huang, X.-Y., Gong, X., Jin, M., Kreft, A., Harrison, B., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152975 · Cited by 163
Thal, D. R., Holzer, M., Rüb, U., Waldmann, G., Günzel, S., Zedlick, D., & Schober, R. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7380 · Cited by 162
Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease
Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Buerger, K., Höft, C., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10253 · Cited by 161
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves
Hu, X., He, W., Diaconu, C., Tang, X., Kidd, G. J., Macklin, W. B., Trapp, B. D., & Yan, R. (2008) · The FASEB Journal · doi:10.1096/fj.08-106666 · Cited by 155
Presenilin diversifies its portfolio
Parks, A. L., & Curtis, D. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.01.008 · Cited by 154
Harrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00227-6 · Cited by 152
Molecular genetics of Alzheimer's disease
Cruts, M., & Broeckhoven, C. V. (1998) · Annals of Medicine · doi:10.3109/07853899809002605 · Cited by 150
Tau-Based Treatment Strategies in Neurodegenerative Diseases
Schneider, A., & Mandelkow�, E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.006 · Cited by 146
Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124
Galasko, D. R., Graff‐Radford, N. R., May, S. J., Hendrix, S. B., Cottrell, B. A., Sagi, S. A., MATHER, G. G., Laughlin, M. A., Zavitz, K. H., Swabb, E. A., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815d1048 · Cited by 123
Wischik, C. M., Bentham, P., Wischik, D., & Seng, K. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.438 · Cited by 118
Therapeutic potential of statins in Alzheimer's disease
Kandiah, N., & Feldman, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.352 · Cited by 113
Höck, C., Maddalena, A. S., Raschig, A., Müller-Spahn, F., Eschweiler, G. W., Huger, K., Hewer, I., Hampel, H. J., Müller-Thornsen, T., Oertel, W. H., et al. (2003) · Amyloid · doi:10.3109/13506120308995249 · Cited by 112
Sankaranarayanan, S., Price, E. A., Wu, G., Crouthamel, M., Shi, X., Tugusheva, K., Tyler, K. X., Kahana, J. A., Ellis, J. D., Jin, L., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130039 · Cited by 101
The use of positron emission tomography in the clinical assessment of dementia
Mazziotta, J. C., Frackowiak, R. S. J., & Phelps, M. E. (1992) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(05)80118-7 · Cited by 95
A randomised , double-blind, placebo-controlled study
Norheim, A. J., Pedersen, E. J., Fø, V., & Berge, L. N. (2001) · Cited by 94
Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
Fowler, C. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.12.001 · Cited by 91
Progress toward the discovery and development of efficacious BACE inhibitors.
Durham, T. B., & Shepherd, T. A. (2006) · PubMed · Cited by 64
Cao, G., Bales, K., DeMattos, R., & Paul, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362173 · Cited by 60
Pharmacological Management of Neurological and Psychiatric Disorders
Enna, S. J., & Coyle, J. T. (1998) · Cited by 57
Leuchtenberger, S., Beher, D., & Weggen, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778793029 · Cited by 56
Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now
Lee, V. M. ‐., & Trojanowski, J. Q. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s328 · Cited by 55
Siemers, E., Friedrich, S. W., Dean, R. A., Sethuraman, G., Demattos, R. B., Jennings, D. L., Tamagnan, G. D., MAREK, K. L., & Seibyl, J. P. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2416 · Cited by 32
Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease
Mohs, R. C., Kawas, C. H., & Carrillo, M. C. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.003 · Cited by 32
Alzheimer's disease: γ-secretase inhibitors
Imbimbo, B. P. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.10.002 · Cited by 32
Green, R. C., Schneider, L. S. S., Hendrix, S. B., Zavitz, K. H., & Swabb, E. A. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.432 · Cited by 25
Alzheimer's disease: epidemiology
Mayeux, R. P. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01218-3 · Cited by 25
Aisen, P. A., Mehran, M., Poole, R., Lavoie, I., Gervais, F., Briand, R., & Garceau, D. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80065-4 · Cited by 21
Tsakanikas, D., Shah, K., Flores, C., Assuras, S., & Relkin, N. R. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2422 · Cited by 14
Harrington, C. M., Sawchak, S. T., Chiang, C., Davies, J. T., Saunders, A. M., Irizarry, M. C., Zvartau-Hind, M. E., van Dyck, C. H., & Gold, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.079 · Cited by 9
Development of a disease‐modifying treatment for Alzheimer's disease: Alzhemed
Aisen, P. S. S. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.03.009 · Cited by 8
S2‐01–04: Aβ turnover in human subjects
Bateman, R. J. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.272 · Cited by 3
Herrling, P. L., Höck, C., & Nitsch, R. M. (2007) · Neurodegenerative Diseases · doi:10.1159/000100891 · Cited by 2
Cited by
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Lipid peroxidation in cell death
Gaschler, M. M., & Stockwell, B. R. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.086 · Cited by 1,828
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
Metadata
- Authors
- Citron, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-05
- Volume
- 9
- Issue
- 5
- Pages
- 387-398
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2033354781
- Cited by
- 1,064
- References
- 111
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.